Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ADX-914 · 2 trials · 2 indications
Severity score is based on evaluation of severity of atopic dermatitis in 4 body regions (head and neck, trunk, upper limbs, and lower limbs). The minimum score is 0 (less severe) and maximum score is 72 (most severe).
Listing and summary of AE incidence
Listing of clinically significant changes in PE findings
Listing and change from baseline to end of study
Listing and change from baseline to end of study
Listing and change from baseline to end of study
Change in 12-lead ECG parameters from baseline to end of study
| Arm | Type | Description |
|---|---|---|
| ADX-914 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Experimental: Cohort 1:1 - 1:6 ADX-914 | EXPERIMENTAL | ADX-914 single SC dose |
| Placebo Comparator: Cohort 1:1 - 1:6 placebo | PLACEBO_COMPARATOR | Placebo single SC dose |
| Experimental: Cohort 2:1- 2:3 | EXPERIMENTAL | ADX-914 multiple SC dose once every 2 weeks for 6 weeks |
| Placebo Comparator: Cohort 2:1- 2:3 | PLACEBO_COMPARATOR | Placebo multiple SC dose once every 2 weeks for 6 weeks |
| Name | Type | Description |
|---|---|---|
| ADX-914 | DRUG | Subcutaneous administration of ADX-914 |
| Placebo | DRUG | Subcutaneous administration of Placebo |
Inclusion Criteria: 1. Age ≥18 years, inclusive, at time of informed consent, with chronic AD (duration of disease ≥3 years) diagnosed by the Eichenfield revised criteria of Hanifin and Rajka. 2. Moderate to severe disease activity at baseline and screening defined as: 1. BSA affected ≥10% 2...
Top 20 of 26 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 6 | PHASE3 | Baricitinib, corticosteroid |
| AbbVie, Inc. | ABBV | 10 | PHASE3 | Upadacitinib, corticosteroids |
| Pfizer Inc. | PFE | 12 | PHASE3 | Abrocitinib |
| Sanofi SA Sponsored ADR | SNY | 13 | PHASE3 | Amlitelimab |
| Regeneron Pharmaceuticals, Inc. | REGN | 4 | PHASE3 | Dupilumab |
| Incyte Corporation | INCY | 3 | PHASE3 | Ruxolitinib, Vehicle |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof , 1%, Vehicle |
| Apogee Therapeutics, Inc. | APGE | 3 | PHASE2 | APG777 |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | GIA632 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Corvus Pharmaceuticals, Inc. | CRVS | 1 | PHASE2 | Soquelitinib |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Nektar Therapeutics | NKTR | 1 | PHASE2 | Rezpegaldesleukin |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE2 | Barzolvolimab |
| Evommune, Inc. | EVMN | 1 | PHASE2 | EVO756 |
| Aclaris Therapeutics, Inc. | ACRS | 1 | PHASE2 | ATI-045 |
| Q32 Bio Inc | QTTB | 1 | PHASE2 | ADX-914 |
| Turn Therapeutics Inc. | TTRX | 1 | PHASE2 | GX-03 |
| Sunshine Biopharma Incorporated | SBFM | 2 | PHASE3 | 611, corticosteroid |
| Co-Diagnostics, Inc. | CODX | 1 | PHASE3 | 611 |